NASDAQ:LUNG Pulmonx Q2 2026 Earnings Report $1.17 -0.05 (-4.10%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.43%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pulmonx EPS ResultsActual EPSN/AConsensus EPS -$0.28Beat/MissN/AOne Year Ago EPSN/APulmonx Revenue ResultsActual RevenueN/AExpected Revenue$22.39 millionBeat/MissN/AYoY Revenue GrowthN/APulmonx Announcement DetailsQuarterQ2 2026Date7/29/2026TimeAfter Market ClosesConference Call DateWednesday, July 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Pulmonx Earnings HeadlinesAzenta (NASDAQ:AZTA) & Pulmonx (NASDAQ:LUNG) Head to Head ContrastJuly 22 at 2:45 AM | americanbankingnews.comPulmonx Corporation (NASDAQ:LUNG) Given Consensus Recommendation of "Hold" by AnalystsJuly 16, 2026 | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 25 at 1:00 AM | Banyan Hill Publishing (Ad)Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026July 15, 2026 | globenewswire.comPulmonx Stock Dividends | NASDAQ:LUNG | BenzingaJune 27, 2026 | benzinga.comPulmonx Shareholders Back Board, Auditor and Pay ProgramJune 4, 2026 | tipranks.comSee More Pulmonx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmonx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmonx and other key companies, straight to your email. Email Address About PulmonxPulmonx (NASDAQ:LUNG) is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes. The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe. Pulmonx supports its commercial portfolio with comprehensive physician training programs, ongoing clinical research collaborations, and robust post-market surveillance initiatives. These efforts help validate long-term safety and efficacy, while also guiding future enhancements and potential label expansions for its technologies. Headquartered in Redwood City, California, Pulmonx maintains an international presence through offices and distribution partners in Europe. Under the leadership of President and Chief Executive Officer Antonio Pizarro, the company continues to advance its mission of improving the quality of life for patients with obstructive lung diseases. Pulmonx remains committed to innovation in minimally invasive therapies and to building strategic relationships with physicians and healthcare institutions worldwide.View Pulmonx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off?Plugging In: How Kinder Morgan Powers Up ProfitsTSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing PowerAMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Upcoming Earnings Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
